(PharmaNewsWire.Com, June 14, 2017 ) The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS mutant patients, who are not eligible to EGFR inhibitors, have a lower number of available treatment options and usually receive fewer lines of treatment compared with patients with RAS wild-type disease. The CRC competitive landscape is going to experience a substantial change, following the approval of pipeline agents exploiting novel mechanisms of actions, especially immunotherapy. Some pipeline drug developers have invested heavily in the identification of potential predictive biomarkers; therefore, these novel agents are expected to induce further patient stratification and to add complexity to the CRC treatment algorithm, which will be also reshaped by the discovery of the predictive value of tumor sidedness.
- The main driver of the growth of the CRC market will be the increasing CRC incident cases, which is attributed to the aging population. - The second strongest driver will be the launch of several efficacious pipeline drugs in the metastatic setting, including immunotherapies that will enter the CRC landscape for the first time, and novel molecular-targeted agents, such as BRAF-targeted therapies. - To gain approval and obtain reimbursement, it is essential for pipeline drugs to demonstrate higher efficacy, in terms of overall survival (OS), compared with available agents. For this reason, almost all the new agents are expected to be positioned in the second- and third-line settings, in which the standard-of-care hurdle is lower. - The entrance of these agents in the CRC market will intensify the competition in the second-line metastatic setting onwards, which will be worsen by the launch of bevacizumab biosimilars, starting in 2018.
- Overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Inquire for Report at http://www.reportsweb.com/inquiry&RW0001740886/buying .
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
